Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Manremyc

Manremyc
2013 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
2 INVESTORS
Description

Developer of a drug and vaccine created to eradicate tuberculosis (TB) by reducing its risk of development. The company's product Nyaditum resae (NR) contains an immunomodulatory compound to control active tuberculosis.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • C/Urgell nº 26, 1
  • 08240 Manresa
  • Spain
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Manremyc’s full profile, request a free trial.

Manremyc Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 10-Jul-2017 00000 Completed Clinical Trials - General
2. Corporate 01-Sep-2014 00000 00000 Completed Clinical Trials - General
1. Angel (individual) 03-Oct-2013 $282K $282K Completed Clinical Trials - General
To view this company’s complete deal history including valuation and funding, request access »

Manremyc Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Teodoro García Trabadelo Corporation Minority 000 0000 000000 0
PuigdeDou Corporation Minority 000 0000 000000 0

Manremyc Executive Team (5)

Name Title Board
Seat
Contact
Info
Pere-Joan Cardona Ph.D Chief Executive Officer & Co-Founder
Cristina Vilaplana Co-Inventor of NR & Co-Founder
Isabel Amat Co-Founder
Jaume Amat Riera Co-Founder
Joan De Dou Advisor